Skip to main content

Advertisement

SpringerLink
Log in

Augmented production of transforming growth factor-β by cultured peripheral blood mononuclear cells from patients with systemic sclerosis

  • Original Paper
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

We sought to determine whether the spontaneous production of transforming growth factor-β (TGF-β) by peripheral blood mononuclear cells (PBMC) is increased in patients with systemic sclerosis (SSc). Culture supernatants of PBMC from SSc patients (n=88) and healthy controls (n=44) were analyzed by enzyme-linked immunosorbent assay. The production of active TGF-β1 and total (active and latent) TGF-β1 by PBMC from patients with limited cutaneous SSc (lSSc) and by PBMC from patients with diffuse cutaneous SSc (dSSc) was significantly elevated compared to the production by PBMC from normal controls. Production of active TGF-β1 by dSSc PBMC was higher than that by lSSc PBMC, although not significantly. Patients with PBMC with increased active or total TGF-β1 production showed significantly shorter disease duration than patients with PBMC with normal production levels. PBMC from patients without anticentromere antibody showed enhanced active TGF-β1 production more frequently than those from patients with anticentromere antibody. PBMC from SSc patients more frequently showed enhanced total TGF-β2 production than PBMC from normal controls. Among each leukocyte subset, spontaneous production of total TGF-β1 was significantly higher in cultured peripheral monocytes/macrophages, but not in T cells, B cells, or NK cells, from patients than from normal controls. Thus, the enhanced production of TGF-β by PBMC may contribute to the disease process in SSc

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2A, B.
Fig. 3.

Similar content being viewed by others

References

  1. Takehara K (2003) Hypothesis: pathogenesis of systemic sclerosis. J Rheumatol 30:755–759

    PubMed  Google Scholar 

  2. Sato S (1999) Abnormalities of adhesion molecules and chemokines in scleroderma. Curr Opin Rheumatol 11:503–507

    Article  PubMed  CAS  Google Scholar 

  3. Denton CP, Abraham DJ (2001) Transforming growth factor- β and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 13:505–511

    Article  PubMed  CAS  Google Scholar 

  4. LeRoy EC, Smith EA, Kahaleh MB, Trojanowska M, Silver RM (1989) A strategy for determining the pathogenesis of systemic sclerosis: is transforming growth factor β the answer? Arthritis Rheum 32:817–825

    PubMed  CAS  Google Scholar 

  5. Sporn MB, Roberts AB (1992) Transforming growth factor- β: recent progress and new challenges. J Cell Biol 119:1017–1021

    Article  PubMed  CAS  Google Scholar 

  6. Snowden N, Coupes B, Herrick A, Illingworth K, Jayson MI, Brenchley PE (1994) Plasma TGF β in systemic sclerosis: a cross-sectional study. Ann Rheum Dis 53:763–767

    PubMed  CAS  Google Scholar 

  7. Higley H, Persichitte K, Chu S, Waegell W, Vancheeswaran R, Black C (1994) Immunocytochemical localization and serologic detection of transforming growth factor β1: association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud’s phenomenon. Arthritis Rheum 37:278–288

    PubMed  CAS  Google Scholar 

  8. Falanga V, Julien JM (1990) Observations in the potential role of transforming growth factor- β in cutaneous fibrosis. Systemic sclerosis. Ann N Y Acad Sci 593:161–171

    PubMed  CAS  Google Scholar 

  9. Giacomelli R, Cipriani P, Danese C, Pizzuto F, Lattanzio R, Parzanese I, et al (1996) Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor β1. J Rheumatol 23:291–296

    PubMed  CAS  Google Scholar 

  10. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590

    Google Scholar 

  11. LeRoy EC, Krieg T, Black C, Medsger TAJ, Fleischmajer R, Rowell N, et al (1988) Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 15:202–205

    PubMed  CAS  Google Scholar 

  12. Sato S, Ihn H, Kikuchi K, Takehara K (1994) Antihistone antibodies in systemic sclerosis: association with pulmonary fibrosis. Arthritis Rheum 37:391–394

    PubMed  CAS  Google Scholar 

  13. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, et al (1993) Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 20:1892–1896

    PubMed  CAS  Google Scholar 

  14. Gruschwitz M, Muller PU, Sepp N, Hofer E, Fontana A, Wick G (1990) Transcription and expression of transforming growth factor type β in the skin of progressive systemic sclerosis: a mediator of fibrosis? J Invest Dermatol 94:197–203

    Article  PubMed  CAS  Google Scholar 

  15. Kulozik M, Hogg A, Lankat-Buttgereit B, Krieg T (1990) Co-localization of Transforming growth factor β2 with α1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 86:917–922

    Article  PubMed  CAS  Google Scholar 

  16. Rossi P, Karsenty G, Roberts AB, Roche NS, Sporn MB, de Crombrugghe B (1988) A nuclear factor 1 binding site mediates the transcriptional activation of a type I collagen promoter by transforming growth factor- β. Cell 52:405–414

    Article  PubMed  CAS  ISI  Google Scholar 

  17. Steen VD (1996) Organ involvement: renal. In: Clements PJ, Furst DE, (eds) Systemic sclerosis. Williams & Wilkins, Baltimore, pp 605–606

  18. Ishikawa O, Ishikawa H (1992) Macrophage infiltration in the skin of patients with systemic sclerosis. J Rheumatol 19:1202–1206

    PubMed  CAS  Google Scholar 

  19. Kraling BM, Maul GG, Jimenez SA (1995) Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 63:48–56

    PubMed  CAS  ISI  Google Scholar 

Download references

Acknowledgements

The authors thank Ms. M. Matsubara and Ms. Y. Yamada for technical assistance.

Author information

Authors and Affiliations

  1. Department of Dermatology, Kanazawa University Graduate School of Medical Science, 920-8641, Kanazawa, Japan

    Minoru Hasegawa, Shinichi Sato & Kazuhiko Takehara

Authors
  1. Minoru Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shinichi Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuhiko Takehara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Minoru Hasegawa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hasegawa, M., Sato, S. & Takehara, K. Augmented production of transforming growth factor-β by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Arch Dermatol Res 296, 89–93 (2004). https://doi.org/10.1007/s00403-004-0472-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-004-0472-5

Keywords

Search

Navigation